On May 17, 2022 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, reported that management will be presenting a corporate overview and participating in 1-on-1 meetings at the upcoming H.C. Wainwright Global Investment Conference May 23-25, 2022 (Press release, Infinity Pharmaceuticals, MAY 17, 2022, View Source [SID1234614727]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright Global Investment Conference Presentation (hybrid)
Date: Tuesday, May 24th, 2022
Time: 7:00 am Eastern Standard Time
Speaker: Adelene Perkins, Chief Executive Officer
Format: Company presentation and virtual 1-on-1 meetings
Webcast Registration Link.
*a replay will be available following the presentation for 90 days